Loading clinical trials...

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01491932•Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

This study is to evaluate long-term safety, tolerability and efficacy for AFQ056 in patients who have completed an AFQ056A study in Parkinson's disease L-dopa induced dyskinesias (PD-LID).

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients who have completed a previous AFQ056A study or are eligible as defined in the core study protocol
•Outpatients
•Patients who have a primary caregiver willing and able to assess the condition of the patient throughout the study in accordance with protocol requirements

Exclusion Criteria

•Atypical or secondary form of Parkinson's disease
•History of surgical treatment for PD including deep brain stimulation
•Advanced, severe, or unstable disease (other than PD)
•History of malignancy
•Evidence of dementia
•Untreated/ineffectively treated mental disorders
•Treatment with certain prohibited medications
•Abnormal lab values or heart abnormalities
•Pregnant or nursing women

Locations (32)

Novartis Investigative Site

Englewood, Colorado, United States

Novartis Investigative Site

Kansas City, Kansas, United States

Novartis Investigative Site

Milwaukee, Wisconsin, United States

Novartis Investigative Site

Innsbruck, Austria

Novartis Investigative Site

Linz, Austria

Novartis Investigative Site

Vienna, Austria

Novartis Investigative Site

London, Ontario, Canada

Novartis Investigative Site

Clermont-Ferrand, France

Novartis Investigative Site

Lille, France

Novartis Investigative Site

Pessac, France

Key Dates

Start Date

March 1, 2012

Primary Completion Date

October 1, 2013

Completion Date

October 1, 2013

Last Updated

December 23, 2020

Enrollment

129

ACTUAL participants

Conditions

DyskinesiasParkinson DiseaseMovement DisordersParkinsonian DisordersAnti-Dyskinesia Agents

Interventions

AFQ056

DRUG

Dyadic Mindfulness for People With Parkinson's Disease and Their Caregivers

NCT06821230

MindfulnessCaregivers+5 more

View study

RECRUITINGNA

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

NCT06692920

Parkinson Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 23, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Inclusion Criteria

Exclusion Criteria

Dyadic Mindfulness for People With Parkinson's Disease and Their Caregivers

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Montelukast in Parkinson Disease

Exercise for Cognitive Excellence in Parkinson's Disease

Botulinum Toxin for the Treatment of Involuntary Movement Disorders